英文标题:Vebreltinib Plus PLB1004 In EGFR-Mutated, NSCLC with MET Amplification or MET Overexpression Following EGFR-TKI 中文标题:伯瑞替尼联合PLB1004治疗EGFR-TKI治疗后出现MET扩增或过表达的EGFR突变NSCLC患者 讲者:李玮(上海市...
英文标题:Furmonertinib Plus Icotinib as First-Line Treatment in EGFR-Mutated NSCLC: Updated Results in L858R and CNS Metastases Groups 中文标题:伏美替尼联合埃克替尼作为EGFR突变NSCLC一线治疗:L858R突变和中枢神经系统转移组的最新结果 讲者:H. Chen(广东医科大学附属医院) 摘要号:P4.07D.02 英文标题:Fur...
Huang J,Fan Q,Lu P, et al .Icotinib in patients with pretrea- ted advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: A single arm, multicenter phase 2 study[J].J Thor Oncol,2016, 11(6):910-917....
et al. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget 6, 16215–16226 (2015). Article PubMed PubMed Central Google Scholar Ha, S. Y. et al. MET overexpression assessed by new interpretation method predicts gene amplification and ...
随着表皮生长因子受体(EGFR)在肺癌中被发现,针对特定基因突变的靶向治疗成为晚期 NSCLC 的重要治疗 方式,并显著延长了患者生存期.尽管第一,二,三代 EGFR-酪氨酸激酶抑制剂(TKI)蓬勃发展,但随着治疗时间 的推移,患者都可能面临耐药和进展.为克服这一难题,基于耐药机制的相关治疗策略正在研究中.本文旨在对 近年来 ...
Icotinib is the first EGFR-TKI to be developed by Chinese researchers. The ICOGEN trial demonstrated that icotinib was noninferior to gefitinib in terms of PFS (4.6 months vs. 3.4 months) in previously treated, nonselected advanced NSCLC patients, and this study fostered the approval of icotinib...
EGFR exon 20 insertion (20ins)-positive non-small-cell lung cancer (NSCLC) is an uncommon disease with limited therapeutic options and dismal prognosis. Here we report the activity, tolerability, potential mechanisms of response and resistance for dual t
As hyperactivation of Ack1 was detected in ASK120067-resistant cells and tumors and was associated with the survival of NSCLC patients, its role in resistance was further investigated. We first asked whether overexpression of Ack1 is sufficient to confer resistance to ASK120067. The results showed...
EGFR‐tyrosine kinase inhibitors play an important role in the treatment of advanced non‐small cell lung cancer (NSCLC).EGFRmutations in advanced NSCLC occur in approximately 35% of Asian patients and 60% of patients with adenocarcinoma. However, the frequency and type ofEGFRmutations in early‐...
Icotinib耐药NSCLC细胞株的建立及其耐药机制研究 研究发现,EGFR-TKI潜在的耐药机制是复杂和多样的,涉及靶蛋白的改变或EGFR的T790M继发突变,EGFR下游通路中PI3K,KRAS,BRAF等基因突变,c-Met扩增或HGF过表达,发生上皮... 李雪 - 《北京交通大学》 被引量: 1发表: 2016年 The Role of HGF/c-MET in Head and Neck...